Development of N=1 RNA Therapies in the Netherlands and Europe
After the development of Milasen in the United States, there has been an increase in the development of antisense oligonucleotide therapies for patients with unique mutations.
2021 OTS Annual Meeting Poster Winner Showcase
Date: October 29th, 2021 Time: 7am-9am Pacific/ 10am-12pm Eastern/ 4pm-6pm Central European Time Description: Are you having post-event letdown ...
Presentations & Networking in a Virtual World
Presenter: Aurélie Lacroix, PhD, Sixfold Bioscience Keith T. Gagnon, Ph.D, Southern Illinois University School of Medicine Date: 25 August ...